Refractory hematologic cancer
diseaseOn this page
Also known as refractory hematologic malignancy
Summary
Refractory hematologic cancer (MONDO:0004111) is a cancer (an umbrella term covering 6 Mondo subtypes) and 9 clinical trials. Top therapeutic interventions include dacomitinib anhydrous, acalabrutinib, and cobimetinib. A subtype of hematopoietic and lymphoid cell neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 9
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | refractory hematologic cancer |
| Mondo ID | MONDO:0004111 |
| DOID | DOID:712 |
| NCIT | C27357 |
| UMLS | C1335724 |
| MedGen | 233400 |
| GARD | 0023831 |
| Is cancer (heuristic) | yes |
Also known as: refractory hematologic cancer · refractory hematologic malignancy
Disease family
This is a subtype of hematopoietic and lymphoid cell neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › refractory hematologic cancer
Related subtypes (7): central nervous system hematopoietic neoplasm, leukemia, lymphoid neoplasm, myeloid neoplasm, histiocytic and dendritic cell neoplasm, myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2, myelodysplastic syndrome with excess blasts
Subtypes (6): refractory hairy cell leukemia, refractory precursor T-lymphoblastic lymphoma/leukemia, refractory plasma cell neoplasm, refractory anemia with excess blasts in transformation, myelodysplastic syndrome with multilineage dysplasia, refractory cytopenia of childhood
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 3 |
| PHASE2 | 2 |
| PHASE1 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03328078 | PHASE1/PHASE2 | RECRUITING | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) |
| NCT00838890 | PHASE1/PHASE2 | TERMINATED | A Study of BMS-863233 in Patients With Hematologic Cancer |
| NCT03739606 | PHASE2 | WITHDRAWN | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer |
| NCT03882203 | PHASE2 | COMPLETED | CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia |
| NCT05205252 | PHASE1/PHASE2 | WITHDRAWN | A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. |
| NCT03878524 | PHASE1 | TERMINATED | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
| NCT04681105 | PHASE1 | COMPLETED | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies |
| NCT05270096 | Not specified | RECRUITING | International Leukemia Target Board |
| NCT05713214 | Not specified | RECRUITING | Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DACOMITINIB ANHYDROUS | 4 | 3 |
| ACALABRUTINIB | 4 | 1 |
| COBIMETINIB | 4 | 1 |
| COPANLISIB | 4 | 1 |
| DAROLUTAMIDE | 4 | 1 |
| ENASIDENIB | 4 | 1 |
| ENTRECTINIB | 4 | 1 |
| HYALURONIDASE (HUMAN RECOMBINANT) | 4 | 1 |
| IBRUTINIB | 4 | 1 |
| IDELALISIB | 4 | 1 |
| LORLATINIB | 4 | 1 |
| MOSUNETUZUMAB | 4 | 1 |
| NERATINIB | 4 | 1 |
| OLAPARIB | 4 | 1 |
| PONATINIB | 4 | 1 |
| RANITIDINE | 4 | 1 |
| TAFASITAMAB | 4 | 1 |
| TAZEMETOSTAT | 4 | 1 |
| VISMODEGIB | 4 | 1 |
| EMAVUSERTIB | 2 | 1 |
| FLOTETUZUMAB | 2 | 1 |
| CHEMBL4747506 | 0 | 1 |
| CHEMBL5187554 | 0 | 1 |
| CHEMBL5276925 | 0 | 1 |
| CHEMBL5398431 | 0 | 1 |
| CHEMBL1171086 | 0 | 1 |
| CHEMBL344227 | 0 | 1 |
| CHEMBL4095008 | 0 | 1 |
| CHEMBL4303155 | 0 | 1 |
| CHEMBL4436406 | 0 | 1 |